Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 10, Issue 4, 2011, Pages 245-257

  Jain, Vikram K ^a   Hawkes, Eliza A ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Biologic agents; Chemotherapy; Colorectal cancer; Metastatic

Indexed keywords

AFLIBERCEPT; AXITINIB; B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PANITUMUMAB; PLACEBO; REGORAFENIB; STEROID; SUNITINIB; TETRACYCLINE; VATALANIB;

ANTIANGIOGENIC THERAPY; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG HYPERSENSITIVITY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INOPERABLE CANCER; LIVER METASTASIS; LOW RISK PATIENT; LUNG NON SMALL CELL CANCER; METASTASIS; METASTATIC COLORECTAL CANCER; MONOTHERAPY; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SKIN TOXICITY; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WILD TYPE; WOUND HEALING IMPAIRMENT;

EID: 84855910793     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.04.001     Document Type: Review

References (123)

1. A. Jemal, R. Siegel, and J. Xu Cancer statistics CA Cancer J Clin 60 2010 277 300
2. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
3. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer Meta-analysis Group in Cancer J Clin Oncol 16 1998 301 308
4. P.M. Hoff, R. Ansari, and G. Batist Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 2001 2282 2292 (Pubitemid 32366981)
5. E. Van Cutsem, C. Twelves, and J. Cassidy Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 2001 4097 4106 (Pubitemid 33049527)
6. H.T. Arkenau, D. Arnold, and J. Cassidy Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials J Clin Oncol 26 2008 5910 5917
7. A. Grothey, D. Sargent, and R.M. Goldberg Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol 22 2004 1209 1214 (Pubitemid 41079833)
8. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
9. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
10. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
11. N. Ferrara Role of vascular endothelial growth factor in the regulation of angiogenesis Kidney Int 56 1999 794 814 (Pubitemid 29411709)
12. J. Folkman, P. Cole, and S. Zimmerman Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment Ann Surg 164 1966 491 502
13. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676 (Pubitemid 36749215)
14. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 2008 579 591
15. R.T. Poon, S.T. Fan, and J. Wong Clinical implications of circulating angiogenic factors in cancer patients J Clin Oncol 19 2001 1207 1225 (Pubitemid 32176299)
16. P. Osterlund, L.M. Soveri, and H. Isoniemi Hypertension and OS in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy Br J Cancer 104 2011 599 604
17. F. Kabbinavar, H.I. Hurwitz, and L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
18. F.F. Kabbinavar, J. Schulz, and M. McCleod Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 2005 3697 3705
19. N.C. Tebbutt, K. Wilson, and V.J. Gebski Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study J Clin Oncol 28 2010 3191 3198
20. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
21. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 2007 4779 4786 (Pubitemid 350086481)
22. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
23. M.R. Mancuso, R. Davis, and S.M. Norberg Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2006 2610 2621 (Pubitemid 44511625)
24. A. Grothey, M.M. Sugrue, and D.M. Purdie Bevacizumab beyond first progression is associated with prolonged OS in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) J Clin Oncol 26 2008 5326 5334
25. H.S. Hochster, L.L. Hart, and R.K. Ramanathan Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study J Clin Oncol 26 2008 3523 3529
26. F.A. Scappaticci, J.R. Skillings, and S.N. Holden Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 2007 1232 1239 (Pubitemid 47299901)
27. S.R. Nalluri, D. Chu, and R. Keresztes Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 300 2008 2277 2285
28. E. Van Cutsem, F. Rivera, and S. Berry Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study Ann Oncol 20 2009 1842 1847
29. C.J. Allegra, G. Yothers, and M.J. O'Connell Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 2009 3385 3390
30. F.A. Scappaticci, L. Fehrenbacher, and T. Cartwright Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Surg Oncol 91 2005 173 180 (Pubitemid 41254420)
31. S.B. Kesmodel, L.M. Ellis, and E. Lin Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases J Clin Oncol 26 2008 5254 5260
32. F.K. Welsh, H.S. Tilney, and P.P. Tekkis Safe liver resection following chemotherapy for colorectal metastases is a matter of timing Br J Cancer 96 2007 1037 1042 (Pubitemid 46608314)
33. E. Chen, D. Jonker, and I. Gauthier Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer Clin Cancer Res 15 2009 1481 1486
34. P.M. Hoff, A. Hochhaus, and B.C. Pestalozzi Cedarinib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients(PTS) with previously untreated metastatic colorectal cancer(MCRC): a randomized, double-blind, phase III study (HORIZON II) Ann Oncol 21 suppl 8 2010 viii1 viii12
35. H. Schmoll, D. Cunningham, and A. Sobrero MFOLFOX6 + cedarinib vs MFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (MCRC): a randomized, double-blind, phase II/III study (HORIZON III) Ann Oncol 21 suppl 8 2010 viii189
36. T.T. Hecht Jr, E. Jaeger, and J. Hainsworth Final OS results of CONFIRM 1, a randomized, double-blind, placebo-controlled phase III trial inpatients with metatatic adenocarcinoma of the colon or rectum receiving first line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX 4) and PTK787/ ZK 222584 (PTK/ZK) or placebo Eur J Cancer 5 suppl 4 2007 3010
37. C. Kohne, E. Bajetta, and E. Lin Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo J Clin Oncol 25 suppl 2007 abstract 4033 www.asco.org Accessed April 29, 2011
38. N. Starling, F. Vzquez, and D. Cunningham Phase I study to evaluate the safety and efficacy of sunitinib in combination with FOLFIRI in treatment-naive metastatic colorectal cancer (mCRC) J Clin Oncol 26 suppl 2008 abstract 3563 www.asco.org Accessed April 29, 2011
39. L.B. Saltz, L.S. Rosen, and J.L. Marshall Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 2007 4793 4799 (Pubitemid 350086483)
40. S. Sharma, V. Abhyankar, and R.E. Burgess A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors Ann Oncol 21 2010 297 304
41. C.R. Garrett, L.L. Siu, and A.B. El-Khoueiry A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy J Clin Oncol 26 suppl 2008 abstract 4111 www.asco.org Accessed April 29, 2011
42. D. Strumberg, M.E. Scheulen, and A. Frost Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC) J Clin Oncol 27 suppl 2009 abstract 356 www.asco.org Accessed April 29, 2011
43. P. Tang, S.J. Cohen, and G.A. Bjarnason Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial J Clin Oncol 26 suppl 2008 abstract 4027 www.asco.org Accessed April 29, 2011
44. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2001 127 137 (Pubitemid 33674041)
45. J. Mendelsohn, and J. Baselga Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer J Clin Oncol 21 2003 2787 2799 (Pubitemid 46606324)
46. M. Scaltriti, and J. Baselga The epidermal growth factor receptor pathway: a model for targeted therapy Clin Cancer Res 12 2006 5268 5272 (Pubitemid 44497237)
47. D. Liu, J. Aguirre Ghiso, and Y. Estrada EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma Cancer Cell 1 2002 445 457 (Pubitemid 41039125)
48. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345 (Pubitemid 38944402)
49. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 2007 2040 2048 (Pubitemid 350106711)
50. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
51. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
52. N.I. Goldstein, M. Prewett, and K. Zuklys Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1995 1311 1318
53. M.C. Prewett, A.T. Hooper, and R. Bassi Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts Clin Cancer Res 8 2002 994 1003 (Pubitemid 34517632)
54. L.B. Saltz, N.J. Meropol, and P.J. Loehrer Sr Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208 (Pubitemid 41079832)
55. H.J. Lenz, E. Van Cutsem, and S. Khambata-Ford Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 2006 4914 4921 (Pubitemid 46630920)
56. E. Van Cutsem, I. Lang, and G. Folprecht Cetuximab plus FOLFIRI: final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome J Clin Oncol 28 suppl 2010 abstract 3570 www.asco.org Accessed April 29, 2011
57. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
58. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 2011 [Epub ahead of print]
59. C. Bokemeyer, C. Kohne, and P. Rougier Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status J Clin Oncol 28 suppl 2010 abstract 3506 www.asco.org Accessed April 29, 2011
60. T.S. Maughan, R. Adams, and C.G. Smith Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial J Clin Oncol 28 suppl 2010 abstract 3502 www.asco.org Accessed April 29, 2011
61. K. Tveit, T. Guren, and B. Glimelius Randomized phase III study of 5-fluorouracil/ folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the Nordic VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation group Ann Oncol 21 suppl 8 2010 viii12
62. A.F. Sobrero, J. Maurel, and L. Fehrenbacher EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2008 2311 2319
63. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664 (Pubitemid 46797944)
64. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
65. S. Tejpar, M. Peeters, and Y. Humblet Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) J Clin Oncol 26 suppl 2008 abstract 4001 www.asco.org Accessed April 29, 2011
66. G. Folprecht, T. Gruenberger, and W.O. Bechstein Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 2010 38 47
67. A.M. Valentini, M. Pirrelli, and M.L. Caruso EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? Curr Opin Mol Ther 10 2008 124 131 (Pubitemid 351498874)
68. M. Moroni, S. Veronese, and S. Benvenuti Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncol 6 2005 279 286 (Pubitemid 40590264)
69. F. Cappuzzo, G. Finocchiaro, and E. Rossi EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients Ann Oncol 19 2008 717 723 (Pubitemid 351461042)
70. A. Sartore-Bianchi, M. Moroni, and S. Veronese Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab J Clin Oncol 25 2007 3238 3245 (Pubitemid 47325607)
71. N. Personeni, S. Fieuws, and H. Piessevaux Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study Clin Cancer Res 14 2008 5869 5876
72. B. Vogelstein, E.R. Fearon, and S.R. Hamilton Genetic alterations during colorectal-tumor development N Engl J Med 319 1988 525 532
73. H.J. Andreyev, A.R. Norman, and D. Cunningham Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study Br J Cancer 85 2001 692 696 (Pubitemid 32929467)
74. S. Stintzing, A. Jung, and U. Vehling-Kaiser Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mcrc): analysis of the randomized trial of the German AIO CRC study group: KRK-0204 Ann Oncol 21 suppl 8 2010 viii189
75. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 2008 5705 5712
76. W.Q. Li, K. Kawakami, and A. Ruszkiewicz BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status Mol Cancer 5 2006 2
77. W. DeRoock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
78. D. Lambrechts, W. De Roock, and H. Prenen The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer. J Clin Oncol www.asco.org 2009 Accessed April 29, 2011
79. S. Khambata-Ford, C.R. Garrett, and N.J. Meropol Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 2007 3230 3237 (Pubitemid 47325606)
80. M. Scartozzi, A. Mandolesi, and R. Giampieri Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan Int J Cancer 127 2010 1941 1947
81. M.E. Lacouture, E.P. Mitchell, and B. Piperdi Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol 28 2010 1351 1357
82. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
83. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
84. T.D. Barber, B. Vogelstein, and K.W. Kinzler Somatic mutations of EGFR in colorectal cancers and glioblastomas N Engl J Med 351 2004 2883 (Pubitemid 40051921)
85. I. Chau, D. Cunningham, and T. Hickish Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study Ann Oncol 18 2007 730 737 (Pubitemid 46523278)
86. M.G. Zampino, E. Magni, and C. Massacesi First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer Cancer 110 2007 752 758 (Pubitemid 47257650)
87. S. Cascinu, R. Berardi, and S. Salvagni A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation Br J Cancer 98 2008 71 76
88. G.A. Fisher, T. Kuo, and M. Ramsey A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer Clin Cancer Res 14 2008 7074 7079
89. J. Stebbing, M. Harrison, and R. Glynne-Jones A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study) Br J Cancer 98 2008 716 719 (Pubitemid 351272618)
90. P. Perrotte, T. Matsumoto, and K. Inoue Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 5 1999 257 265 (Pubitemid 29085177)
91. S.J. Kim, H. Uehara, and T. Karashima Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice Clin Cancer Res 9 2003 1200 1210 (Pubitemid 36323730)
92. Y.D. Jung, P.F. Mansfield, and M. Akagi Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model Eur J Cancer 38 2002 1133 1140 (Pubitemid 34468020)
93. J.R. Tonra, D.S. Deevi, and E. Corcoran Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy Clin Cancer Res 12 2006 2197 2207
94. L.B. Saltz, H.J. Lenz, and H.L. Kindler Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561 (Pubitemid 350035312)
95. J. Tol, M. Koopman, and A. Cats Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
96. J.R. Hecht, E. Mitchell, and T. Chidiac A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer J Clin Oncol 27 2009 672 680
97. R.J. Mayer Targeted therapy for advanced colorectal cancermore is not always better N Engl J Med 360 2009 623 625
98. R. Adam, V. Delvart, and G. Pascal Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival discussion 657-58 Ann Surg 240 2004 644 657
99. H.I. Hurwitz, J. Yi, and W. Ince The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer Oncologist 14 2009 22 28
100. Grothey A. EGFR antibodies in colorectal cancer: where do they belong? J Clin Oncol 28:466870.
101. I. Chau, and D. Cunningham Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 100 2009 1704 1719
102. International Registry of Liver Metastasis of Colorectal Cancerhttps:// www.livermetsurvey.org/ Accessed January 6, 2011
103. Y. Fong, A.M. Cohen, and J.G. Fortner Liver resection for colorectal metastases J Clin Oncol 15 1997 938 946 (Pubitemid 27106275)
104. R. Adam, E. Avisar, and A. Ariche Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal Ann Surg Oncol 8 2001 347 353 (Pubitemid 32422861)
105. Y. Nakajima, M. Nagao, and S. Ko Clinical predictors of recurrence site after hepatectomy for metastatic colorectal cancer Hepatogastroenterology 48 2001 1680 1684 (Pubitemid 34003503)
106. N.J. Petrelli Perioperative or adjuvant therapy for resectable colorectal hepatic metastases J Clin Oncol 26 2008 4862 4863
107. S. Gill, C.L. Loprinzi, and D.J. Sargent Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22 2004 1797 1806 (Pubitemid 41095169)
108. R. Sauer, H. Becker, and W. Hohenberger Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 2004 1731 1740
109. J. Figueras, J. Torras, and C. Valls Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients Dis Colon Rectum 50 2007 478 488 (Pubitemid 46701611)
110. R. Parks, M. Gonen, and N. Kemeny Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents discussion 761-3 J Am Coll Surg 204 2007 753 761 (Pubitemid 46661187)
111. X. Wang, D.L. Hershman, and J.A. Abrams Predictors of survival after hepatic resection among patients with colorectal liver metastasis Br J Cancer 97 2007 1606 1612 (Pubitemid 350249362)
112. G. Portier, D. Elias, and O. Bouche Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 2006 4976 4982 (Pubitemid 46631399)
113. M. Ychou, W. Hohenberger, and S. Thezenas A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer Ann Oncol 20 2009 1964 1970
114. E. Mitry, A.L. Fields, and H. Bleiberg Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials J Clin Oncol 26 2008 4906 4911
115. B. Nordlinger, H. Sorbye, and B. Glimelius Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 2008 1007 1016 (Pubitemid 351392040)
116. C.J. Allegra, G. Yothers, and M.J. O'Connell Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08 J Clin Oncol 29 2011 11 16
117. S.R. Alberts, D.J. Sargent, and T.C. Smyrk Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147 J Clin Oncol 28 suppl 2010 www.asco.org Accessed April 29, 2011
118. J. Pfannschmidt, H. Dienemann, and H. Hoffmann Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series Ann Thorac Surg 84 2007 324 338 (Pubitemid 46921128)
119. A. Falcone, S. Ricci, and I. Brunetti Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 2007 1670 1676 (Pubitemid 46797946)
120. G. Folprecht, A. Grothey, and S.Raab Alberts Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann Oncol 16 2005 1311 1319 (Pubitemid 41158476)
121. B. Gruenberger, D. Tamandl, and J. Schueller Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 26 2008 1830 1835
122. R. Wong, C. Saffery, and Y. Barbachano BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection Eur J Cancer Suppl 7 2009 344
123. Cetuximab for the first-line treatment of metastatic colorectal cancer http://www.nice.org.uk/nicemedia/live/12216/45198/45198.pdf Accessed January 11, 2011